Literature DB >> 26359304

Cx30 exhibits unique characteristics including a long half-life when assembled into gap junctions.

John J Kelly1, Qing Shao1, Daniel J Jagger2, Dale W Laird3.   

Abstract

In the present study we investigated the life cycle, trafficking, assembly and cell surface dynamics of a poorly characterized connexin family member, connexin 30 (Cx30; also known as GJB6), which plays a critical role in skin health and hearing. Unexpectedly, Cx30 localization at the cell surface and gap junctional intercellular communication was not affected by prolonged treatments with the endoplasmic reticulum (ER)-Golgi transport inhibitor brefeldin A or the protein synthesis inhibitor cycloheximide, whereas Cx43 (also known as GJA1) was rapidly cleared. Fluorescent recovery after photobleaching revealed that Cx30 plaques were rebuilt from the outer edges in keeping with older channels residing in the inner core of the plaque. Expression of a dominant-negative form of Sar1 GTPase led to the accumulation of Cx30 within the ER, in contrast to a report that Cx30 traffics via a Golgi-independent pathway. Co-expression of Cx30 with Cx43 revealed that these connexins segregate into distinct domains within common gap junction plaques, suggesting that their assembly is governed by different mechanisms. In summary, Cx30 was found to be an unusually stable, long-lived connexin (half-life >12 h), which may underlie its specific role in the epidermis and cochlea.
© 2015. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Connexin; Connexin 30; Cx30; Gap junction; Life cycle; Trafficking

Mesh:

Substances:

Year:  2015        PMID: 26359304     DOI: 10.1242/jcs.174698

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  7 in total

Review 1.  Therapeutic strategies targeting connexins.

Authors:  Dale W Laird; Paul D Lampe
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 2.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

3.  Neuronal Activity Drives Astroglial Connexin 30 in Perisynaptic Processes and Shapes Its Functions.

Authors:  Grégory Ghézali; Flora Vasile; Nathan Curry; Marcus Fantham; Giselle Cheung; Pascal Ezan; Martine Cohen-Salmon; Clemens Kaminski; Nathalie Rouach
Journal:  Cereb Cortex       Date:  2020-03-21       Impact factor: 5.357

4.  Connexin30.3 is expressed in mouse embryonic stem cells and is responsive to leukemia inhibitory factor.

Authors:  Mikako Saito; Yuma Asai; Keiichi Imai; Shoya Hiratoko; Kento Tanaka
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

5.  Comparative Analysis of Cx31 and Cx43 in Differentiation-Competent Rodent Keratinocytes.

Authors:  Akina Au; Qing Shao; Kyra K White; Sergiu A Lucaciu; Jessica L Esseltine; Kevin Barr; Dale W Laird
Journal:  Biomolecules       Date:  2020-10-14

6.  Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia.

Authors:  John J Kelly; Jessica L Esseltine; Qing Shao; Ethylin Wang Jabs; Jacinda Sampson; Mari Auranen; Donglin Bai; Dale W Laird
Journal:  Mol Biol Cell       Date:  2016-05-25       Impact factor: 4.138

7.  The dynamic Nexus: gap junctions control protein localization and mobility in distinct and surprising ways.

Authors:  Sean McCutcheon; Randy F Stout; David C Spray
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.